Radiopharma companies merge after one receives surprise FDA rejection
Telix Pharmaceuticals is acquiring ITM Isotope Technologies Munich in a deal valued at over $1.65 billion to expand its footprint in the radiopharmaceutical cancer treatment market. The merger aims to challenge the current market dominance of Novartis in the field of targeted radioactive isotope therapies.
Why it matters
This consolidation signals significant growth and investment in the radiopharmaceutical sector, which is becoming a critical frontier in oncology treatment.
Camille MacMillin/STAT By Allison DeAngelis
Biotech Startups and Venture Capital Reporter
Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “ The Readout Loud .” You can reach Allison on Signal at AllisonDeAngelis.01.
ITM Isotope Technologies Munich SE and Telix Pharmaceuticals, two leading companies in the burgeoning radiopharmaceuticals field, are merging in a deal worth at least $1.65 billion.
Under the deal, Telix will acquire all shares of the privately held company ITM. Telix could also pay another $700 million to shareholders, if ITM’s lead drug meets regulatory and sales goals.
The merger creates another well-resourced company in the radiopharmaceutical field, which is currently dominated by Novartis. These medicines work by delivering radioactive isotopes directly to cancer cells. Novartis supercharged the field with the launch of its two such treatments in 2018 and 2022.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in